2016 ACVIM Forum Research Abstract Program

Forty-four adult dogs (22 Test, 22 Control) were enrolled and completed the study. During the course of the study 18% of all dogs had no reported dermatological clinical signs whereas 82% developed a positive CADESI and/or pruritis score. CADESI and pruritis scores rose significantly from 0 at all subsequent time points but were generally low. Mean AE SEM CADESI scores at weeks 4, 8, 12 and 16 were; 2.6 AE 0.98, 5.8 AE 2.47, 8.6 AE 3.31 and 6.6 AE 1.91 respectively. Mean AE SEM pruritis scores were 0.5 AE 0.16 at week 4 and were highest at week 16; 1.2 AE 0.16. Incidence, location and types of clinical signs manifested were not different between groups. Medications were only dispensed to dogs with a positive CADESI and/or pruritis score, which was 66% of all dogs (73% of Control versus 59% of Test). Medications dispensed were categorized as a topical containing a glucocorticoid, a systemic antihistamine and/or a systemically administered glucocorticoid. An event history analysis revealed that time until prescribing topical medications was highly similar between groups (Test 98 AE 7.0 versus Control 100 AE 5.2 days) but was less so for antihistamines (Test 62 AE 4.1 versus Control 55 AE 3.3 days) and systemic glucocorticoids (Test 105 AE 4.4 versus Control 90 AE 6.4 days).